EUGENE ROSENMAN: Open Payments
NPI 1659433787 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$394 in 15 payments from 6 companies in 2025. Trend: 2023 $133 · 2024 $308 · 2025 $394
Food & beverage: $394
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $104 |
| E.R. Squibb & Sons, L.L.C. | 4 | $102 |
| Teva Pharmaceuticals USA, Inc. | 2 | $77 |
| Neurocrine BioSciences, Inc. | 3 | $75 |
| Indivior Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Products named: REXULTI, COBENFY, AUSTEDO XR, INGREZZA, SUBLOCADE, Qelbree.
Industry payments across NV — which companies pay providers there.
